Diagnostic Pathology Conference 2018
OVERVIEW
Diagnostic Pathology Conference is organized by University of Texas MD Anderson Cancer Center and will be held on Feb 03, 2018 at University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America.
The target audience for this medical event is practicing pathologists and pathology trainees. This CME Conference has been approved for a maximum of 7.25 AMA PRA Category 1 Credits.
Conference Description :
This live activity will update general surgical pathologists on the application of current classification systems of solid neoplasms and precursor lesions. These include molecular classification of bladder tumors, evaluation of circulating tumor cell in lung cancer, classification of neurofibromatosis, classification of gastrointestinal tumors especially pancreatic endocrine neoplasms and mucinous cystic lesions, gynecologic tumors as well as thyroid neoplasms. There are many new molecular and genetic approaches that can be used to classify solid neoplasms.
This activity will also inform the target audience of the significant problematic diagnostic issues and provide them with the information needed to avoid making diagnostic errors when confronted with these scenarios. Research on recently implemented diagnostic and prognostic molecular tests will be presented as well, so attendees can use this information to improve the accuracy of their clinical and histopathologic diagnoses and classification.
The activity content is expected to increase the attendees' knowledge of the appropriate clinical use of diagnostic molecular testing, alter the attendees practice patterns to enable them to make more accurate diagnoses, and inform them of specific areas of diagnostic difficulty that will permit them to avoid diagnostic errors.
Conference Objectives :
• Apply updated diagnostic criteria and new molecular tests for proper classification and treatment of neoplastic lesions (knowledge, competence, performance, patient outcomes)
• Incorporate emerging and newly established biomarkers in classification of neoplasms and high risk lesions (knowledge, competence, performance, patient outcomes)
• Practice appropriate use of molecular testing and tumor diagnosis (knowledge, competence, performance)
The target audience for this medical event is practicing pathologists and pathology trainees. This CME Conference has been approved for a maximum of 7.25 AMA PRA Category 1 Credits.
Conference Description :
This live activity will update general surgical pathologists on the application of current classification systems of solid neoplasms and precursor lesions. These include molecular classification of bladder tumors, evaluation of circulating tumor cell in lung cancer, classification of neurofibromatosis, classification of gastrointestinal tumors especially pancreatic endocrine neoplasms and mucinous cystic lesions, gynecologic tumors as well as thyroid neoplasms. There are many new molecular and genetic approaches that can be used to classify solid neoplasms.
This activity will also inform the target audience of the significant problematic diagnostic issues and provide them with the information needed to avoid making diagnostic errors when confronted with these scenarios. Research on recently implemented diagnostic and prognostic molecular tests will be presented as well, so attendees can use this information to improve the accuracy of their clinical and histopathologic diagnoses and classification.
The activity content is expected to increase the attendees' knowledge of the appropriate clinical use of diagnostic molecular testing, alter the attendees practice patterns to enable them to make more accurate diagnoses, and inform them of specific areas of diagnostic difficulty that will permit them to avoid diagnostic errors.
Conference Objectives :
• Apply updated diagnostic criteria and new molecular tests for proper classification and treatment of neoplastic lesions (knowledge, competence, performance, patient outcomes)
• Incorporate emerging and newly established biomarkers in classification of neoplasms and high risk lesions (knowledge, competence, performance, patient outcomes)
• Practice appropriate use of molecular testing and tumor diagnosis (knowledge, competence, performance)
KEY DATES
03 Feb, 2018
Event Start Date
03 Feb, 2018
Event End Date
SPECIALITIES
PathologySUGGESTED HOTELS
CONFERENCE VENUE
University of Texas MD Anderson Cancer Center
Quick Links